The Liver Meeting Digital Experience™ (TLMdX)

Study offers clues on which patients may safely stop HBV therapy

Elvira Manzano, 20211215000000

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

Increased serum iron may hint at HCC risk in NAFLD patients

Roshini Claire Anthony, 20211207180001

Increased serum iron or transferrin saturation levels in individuals with non-alcoholic fatty liver disease (NAFLD) may point to an increased risk of hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting Digital Experience™.

Switching to TAF helps improve virologic response in HBV patients in real world

Pearl Toh, 20211206140100

Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.

Interim findings boost therapeutic potential of lanifibranor for NASH

Audrey Abella, 20211206100000

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Non-overweight NAFLD patients have poor liver transplant outcomes

Roshini Claire Anthony, 20211203180001

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.

Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients

Audrey Abella, 20211202152815

In a pooled post hoc analysis of three phase III trials, a novel two-dose hepatitis B (hep-B) vaccine regimen trumped the traditional three-dose regimen in inducing seroprotection in patients with chronic liver disease (CLD).

Statins help preserve liver function in chronic liver disease

Statins not only good for the heart, but also the liver

Pearl Toh, 20211127130100

Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden

Tristan Manalac, 20211122090000

Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).

In the waiting line for liver transplants: Women remain disadvantaged

Jairia Dela Cruz, 20211120090000

Access to liver transplantation suffers from a persistent and unacceptable gender gap, with female candidates on the wait list being much less likely to receive a transplant and facing a higher risk of dying than their male counterparts, according to an expert.

Protease-based liquid biopsy a promising approach for diagnosing fatty liver disease

Jairia Dela Cruz, 20211119170000

A liquid biopsy platform that utilizes protease biosensors can detect nonalcoholic steatohepatitis with pinpoint accuracy in both mice and humans.